Redwoods Acquisition's

The competitive landscape for Alzheimer's disease therapeutics includes anti-amyloid antibodies such as aducanumab (Biogen: Aduhelm) and lecanemab (Lilly: Leqembi), both of which received FDA approval. Aducanumab was recently withdrawn from the market due to lack of effectiveness and serious side effects. Multiple large and early-stage pharmaceutical companies are developing treatments for Alzheimer's disease. Few companies reference Klotho or Klotho gene therapy; ADvantage Therapeutics mentions Klotho, while Unity Biotechnology, a startup focused on drugs targeting senescent cells, is the leading competitor in Klotho gene therapy. Unity Biotechnology has licensed Dubal Klotho technology but has not published data or clinical trials. Regulatory approval is required in Europe, Japan, and other countries to market products outside the U.S., with each jurisdiction imposing its own requirements. Competitors identified include ADvantage Therapeutics, Biogen, Bristol-Myers/Celgene, Lilly, Roche, and Unity Biotechnology.